DR. PETER M. SADOW, M.D., PH.D.

Plain English
This study looked at a special type of immune cell called CCR7 dendritic cells in tumors to understand how their location affects the body’s ability to fight cancer. Researchers found that these cells cluster near blood vessels, and when they interact with regulatory immune cells, they can become suppressed and less effective at activating T cells, which are crucial for fighting tumors. By removing regulatory cells or using certain cancer treatments, they were able to boost the action of CCR7 dendritic cells and improve T cell responses in treating tumors. Who this helps: This benefits cancer patients undergoing immunotherapy.

Plain English
This study focused on pheochromocytomas and extra-adrenal paragangliomas, which are rare tumors that can produce hormones and are often linked to genetic conditions. Researchers noted that while the biology of these tumors hasn’t changed, our understanding of their genetics and how to manage them has improved significantly. About 40% of these tumors have inherited mutations, which influences how doctors predict their behavior and approach treatment. Who this helps: This information benefits patients with these tumors and their healthcare providers by improving diagnosis and management strategies.

Plain English
This study looked at a type of immune cell called neutrophils in various types of cancer and found that a specific state of these cells, marked by a molecule called CCL3, helps tumors grow. Researchers analyzed over 190 tumors and discovered that CCL3-producing neutrophils thrive in low-oxygen areas of tumors, which encourages their survival and promotes tumor growth. Understanding this relationship is important because it could lead to new strategies for targeting these cells to slow cancer progression. Who this helps: This helps cancer patients and doctors looking for new treatment options.

Plain English
This study focused on a type of kidney tumor called papillary renal neoplasm with reverse polarity, which is generally low-risk and has a good outlook. The researchers described two patients; one has shown no signs of progression while being monitored, and the other has been healthy for 16 years after surgery. Recognizing the specific features of this tumor is crucial because it indicates that patients may do well with less aggressive treatments, like monitoring or a less invasive surgery. Who this helps: Patients with this type of kidney tumor.

Plain English
This study looked at a new treatment approach for patients with head and neck cancers that haven't responded to standard immunotherapy. Researchers gave a low-dose medication called 5-azacytidine alongside other drugs to see if it could improve the immune response and overall patient survival. They found that 38% of the patients had significant increases in certain immune markers, and the average survival was 16.3 months, with 58% of patients living longer than 12 months after treatment. Who this helps: This benefits patients with advanced head and neck cancers who have not responded to traditional treatments.

Plain English
This study looked at a rare type of tumor called dedifferentiated liposarcoma that formed near the kidney in an older man. The tumor was very large, measuring 16.3 cm, and was mostly non-viable with only about 10% being active cancer cells, which were split between a less aggressive type and a more aggressive type. The patient had surgery to remove the tumor, and after six months, he was healthy and had no signs of the cancer returning. Who this helps: This information is useful for doctors treating patients with rare kidney tumors.

Plain English
This study looked at the immune cells in the thyroids of patients with two different autoimmune diseases: Hashimoto's thyroiditis (HT) and Graves' Disease (GD). Researchers examined over 600,000 cells and found that, even though HT and GD have different symptoms and causes, they share similar immune cell patterns that affect thyroid function. Understanding these shared immune responses is important for developing better treatments for both conditions. Who this helps: This helps patients with thyroid autoimmune diseases.

Plain English
This study looked at how sudden hearing loss in both ears might be a sign of cancer that has spread to the brain, specifically from colorectal cancer. Using MRI and CT scans, the researchers found a mass in the skull base of a patient that was causing this hearing loss. This is important because early detection of such masses can lead to quicker treatment and better outcomes for patients. Who this helps: This helps patients experiencing unexplained hearing loss and their doctors.

Plain English
Researchers studied how to better classify and understand the severity of renal pelvic urothelial carcinoma, a type of kidney cancer, by analyzing 141 patients who had surgery. They found that the current staging system (called TNM) does not effectively predict survival differences for many tumor stages. However, by simplifying the staging criteria, they revealed that tumors invading the outer layer of the kidney (cortex) are linked to much poorer survival rates compared to those that do not. Who this helps: This helps doctors better predict patient outcomes and tailor treatment for kidney cancer patients.

Plain English
This study examined how certain structures in the tumor called tertiary lymphoid structures (TLS) can help predict which patients with head and neck cancer will respond to a specific type of immunotherapy known as immune checkpoint blockade (ICB). Researchers looked at tumor samples from 20 patients, finding that those who responded to treatment had more B cells present and better survival rates when TLS were located close to the tumor. The study also showed that measuring TLS density could predict treatment response with 80% accuracy, suggesting it may be a better indicator than the currently used marker. Who this helps: This helps patients with recurrent head and neck cancer by improving treatment prediction and outcomes.

Plain English
This study looked at 52 thyroid nodules with specific genetic mutations to see how often they were cancerous. Among the nodules tested, 65% turned out to be malignant, with varying risks depending on the type of mutations present. This research matters because it highlights that many nodules with certain mutations can be benign, suggesting that less invasive treatments could be appropriate for patients, rather than the total thyroid removal usually recommended. Who this helps: This information benefits patients with thyroid nodules and their doctors by reducing unnecessary surgeries.

Plain English
Researchers studied different types of tumors found in the salivary glands, specifically looking at certain benign and early-stage cancerous lesions linked to a condition called pleomorphic adenoma. They found that many of these lesions, even with some unusual cell features, do not lead to recurrence or spread of cancer if they remain contained within the tumor. This is important because it suggests that some terms used to describe these lesions might cause unnecessary worry and treatment, and simpler names that reflect their generally harmless nature could be more appropriate.

Plain English
Adenoid cystic carcinoma (ACC) is a deadly cancer that doesn't respond well to current treatments because tumors hide from the immune system—they have very low levels of a protein called HLA class I that the immune system needs to recognize and attack cancer cells. Researchers discovered that treating ACC tumors with immune-activating drugs called STING agonists can turn this protein back on, and when they tested this approach in one patient combined with an existing immunotherapy drug, the tumor shrank by 70%. This finding suggests that turning HLA class I back on with STING agonists could finally make immunotherapy work for ACC patients.

Plain English
Researchers developed a new blood test using advanced DNA sequencing to detect HPV-associated head and neck cancers early, before symptoms appear, and compared it to three other blood-based detection methods. The new sequencing test detected cancer 98.7% of the time it was present and correctly identified healthy people 98.7% of the time—significantly better than existing blood tests. This breakthrough matters because HPV-related head and neck cancers are becoming more common, yet doctors currently have no way to catch them early when treatment is most effective.

Plain English
Researchers developed a highly sensitive blood test that detects tiny amounts of HPV cancer DNA left in patients after surgery for HPV-related head and neck cancer. They found that patients whose blood still contained this cancer DNA had much worse outcomes—only 60% stayed cancer-free for 2 years compared to 100% of patients with no detectable DNA—and this blood test was better at predicting who would relapse than current methods doctors use. The test could also spot cancer coming back up to 17 months before it shows up on scans or causes symptoms, giving doctors an early warning system to decide whether patients need additional treatment like chemotherapy or radiation.

Plain English
This study looked at a rare type of testicular tumor called spermatocytic tumors (STs), which primarily affect older men. Researchers analyzed 27 samples from 25 patients and found two main types of STs: one type had specific mutations associated with cancer, while the other did not. They discovered that aggressive tumors often had mutations in a gene called TP53 and changes in chromosome 12, which suggest these tumors might behave similarly to other more serious forms of testicular cancer. Who this helps: This research benefits doctors and patients by providing insights into how some spermatocytic tumors might develop into more aggressive forms.

Plain English
This study looked at rare tumors that start in the nose and sinus areas and grow in the temporal bone, which is part of the skull. Researchers reviewed 76 cases, finding that 51% of these tumors were secondary, meaning they developed after tumors in the nose and sinuses, often about a year later. These findings are important because they suggest that certain tumors can spread through a nearby tube, increasing the need for doctors to consider this when diagnosing ear masses. Who this helps: Patients with tumors in the ear or those with a history of sinonasal tumors.

Plain English
This study focused on a type of thyroid cancer called columnar cell papillary thyroid carcinoma (CC-PTC), analyzing its characteristics and how they relate to patient outcomes. The research examined 12 cases and found that 73% of the tumors tested positive for the protein ER, and 50% for CDX2. Some tumors behaved more like aggressive cancers, while others were less invasive, suggesting that this type of cancer has a mix of different genetic backgrounds and behaviors. Who this helps: This information is useful for doctors diagnosing and treating patients with this specific type of thyroid cancer.

Plain English
This research reviewed oncocytic thyroid carcinoma, a rare type of thyroid cancer that makes up about 5% of all thyroid cancers. The study found that this cancer has unique genetic features and behaves differently than other thyroid cancers, including higher chances of spreading to lymph nodes and not responding well to radioiodine treatment. Recognizing these differences is crucial for creating better treatment plans tailored specifically for patients with oncocytic thyroid carcinoma. Who this helps: This helps patients with oncocytic thyroid carcinoma and their doctors in managing their treatment effectively.

Plain English
Researchers studied the use of a test called RASQ61R immunohistochemistry (RASQ61R-IHC) to detect specific mutations in medullary thyroid carcinoma (MTC) before surgery. They found that, when using strict criteria for a positive result, the test was 100% accurate in identifying patients with a specific RAS mutation and could help differentiate between inherited and sporadic cases of MTC. This matters because it can guide more precise genetic testing for patients, potentially streamlining their diagnosis and treatment options. Who this helps: This helps patients with medullary thyroid carcinoma by ensuring they receive appropriate genetic testing.

Plain English
This study looked at how certain immune cells in head and neck cancer tumors can predict whether patients will respond well to a treatment called immune checkpoint blockade (ICB). The researchers found that patients who responded to ICB had a higher amount of B lymphocytes (CD20+ cells) in their tumors compared to those who did not respond (22% vs. lower levels). Additionally, certain structures called Tertiary Lymphoid Structures (TLS) near the tumors were linked to better survival rates, with a 4% higher chance of overall survival among patients with these structures. Who this helps: This research helps patients with head and neck cancer by identifying better predictors of treatment response.

Plain English
This study looked at how two methods of cancer treatment—using a TLR8 agonist along with PD-1 blockade—work together in patients with head and neck cancer. The researchers examined tumor samples before and after treatment and found that patients who received both therapies showed significant increases in immune system activity, including more dendritic cells that help fight tumors and higher densities of cytotoxic T-cells, indicating a stronger immune response. This matters because understanding how these treatments enhance the immune response can lead to better cancer therapies. Who this helps: This research benefits cancer patients, especially those with head and neck squamous cell carcinoma.

Plain English
This study examined a rare type of cancer in the tongue of a 46-year-old man, which was driven by a specific genetic mutation known as the FUS::CREM fusion. The tumor was about 4 cm in size and displayed aggressive features, although it had not spread to nearby lymph nodes. After surgery and radiation treatment, the patient showed no signs of the cancer returning after four months. Who this helps: This information is valuable for doctors treating patients with rare head and neck cancers.

Plain English
The researchers studied a specific genetic mutation, RAS p.Q61R, in 217 thyroid nodules to see how common it is and how it relates to cancer risk. They found that this mutation appears in a significant percentage of thyroid nodules, but most of the tumors associated with it are low-risk and do not lead to serious health issues. This is important because it shows a reliable and quick way to identify these mutations, helping doctors decide how to monitor and treat patients with thyroid nodules.

Plain English
Researchers looked at 5,030 thyroid cancer samples and found 17 tumors with mutations in a specific gene family—11 where this mutation was the main cancer driver and 6 where it was a secondary mutation that might help cancer resist treatment. They discovered that some of these mutations could be targeted with existing drugs, but doctors aren't currently looking for them because they're not well-known. This matters because identifying these mutations in thyroid cancer patients could open up new treatment options that don't work for other types of thyroid cancer, potentially improving outcomes for people who have these specific mutations.

Plain English
This study looked at how doctors can work together to better diagnose and manage problems with the parathyroid glands, which are important for hormone regulation in the body. It specifically examined how information gathered before, during, and after surgery can improve patient outcomes. Understanding parathyroid diseases can lead to more effective treatments, ultimately helping to prevent complications. Who this helps: This benefits patients with parathyroid diseases and the doctors treating them.

Plain English
This research studied how a drug called lenvatinib affects a deadly type of cancer known as anaplastic thyroid carcinoma (ATC), particularly focusing on structures called pericytes that are found in the tumor's environment. The researchers found that ATC tumors have more pericytes compared to normal thyroid tissue, and when ATC cells are grown with pericytes, they respond better to lenvatinib—showing reduced growth. Understanding how pericytes influence lenvatinib's effectiveness is important because it could lead to better treatment strategies for ATC patients. Who this helps: Patients with anaplastic thyroid carcinoma.

Plain English
This research examined the environments around tumors in 52 patients with head and neck cancers to see how they affect cancer growth and patient outcomes. It found that the way a type of immune cell, called macrophages, behaves (specifically referenced as CS macrophage polarity) is strongly linked to how well patients do, helping to identify either factors that promote or fight against tumors. This matters because understanding these behaviors can improve treatment strategies for cancer. Who this helps: Patients with head and neck cancers.

Plain English
This study looked at seven rare tumors called PEComas found in the adrenal glands, which can be challenging to diagnose because they look similar to other tumors. Among the patients studied, five were men and two were women with a median age of 63 years. Four of the tumors were considered malignant, and one patient experienced disease that spread at 18 months after treatment, while two patients remained free of disease at their last check-up, 60 and 25 months later. Who this helps: This research is important for pathologists and doctors who treat patients with adrenal tumors, helping them recognize and diagnose these uncommon tumors more effectively.

Plain English
The study looked at how intraoperative ultrasound (IOUS) images can help during surgery for oral tongue cancers by examining the shape and boundaries of the tumors. Out of 29 patients, the researchers found that while the ultrasound patterns didn't strongly correlate with the final tissue analysis, an infiltrative pattern seen on ultrasound was linked to a higher risk of close surgical margins, which can mean incomplete removal of the cancer. This is important because having close margins can lead to a higher chance of cancer recurrence. Who this helps: This helps patients undergoing surgery for oral tongue cancers.

Plain English
This research paper focuses on thyroid cancers with a specific genetic change called NTRK gene fusions. Researchers found that these fusions are rare but important because they can be treated with targeted therapies that have been approved for advanced thyroid cancers. The paper recommends that doctors should test for these gene fusions early in the process for patients who have hard-to-treat cancers or those that have spread, to determine if they can benefit from these newer treatments. Who this helps: Patients with advanced thyroid cancer who may be eligible for targeted therapies.

Plain English
This research paper looks at a specific type of cancer found in the nose and sinuses called IDH2-mutated sinonasal tumors. The study found that out of 82 cases, these tumors often occur in patients around 60 years old, with the tumors typically measuring about 5 cm. While most patients (65%) can have their tumors surgically removed, there is still a high chance of recurrence and metastasis (60% and 40%, respectively), but patients with this mutation tend to have better outcomes compared to others without it. Who this helps: Patients with IDH2-mutated sinonasal tumors and their doctors.

Plain English
This research paper looks at how advances in molecular testing are changing the diagnosis and treatment of thyroid nodules, which are common lumps in the thyroid gland. While fine needle aspiration biopsies can help identify cancer, results are unclear in about 30% of cases, leading to the need for more tests. The study highlights that new genetic testing methods are now essential for managing thyroid cancer, offering clearer information for doctors and personalized treatment options for patients. Who this helps: This helps patients with thyroid nodules and thyroid cancer.

Plain English
Researchers studied 131 patients with HPV-positive throat cancer who had surgery to remove lymph nodes from their necks, looking at where the cancer had spread. They found that unusual spread patterns—where cancer appears in lower neck levels while skipping the upper levels—happened in only 5% of patients. These results suggest surgeons may be able to safely skip removing lymph nodes from the lowest neck level in some HPV-positive throat cancer patients, potentially reducing surgery complications without compromising cancer treatment.

Plain English
Researchers injected a near-infrared dye called indocyanine green into cancer patients and found that cancer cells glow differently than healthy cells when measured by how long the glow lasts (rather than how bright it is). This difference in glow duration remained consistent across different cancer types and could identify tumors with over 97% accuracy, even at the cellular level. This matters because current surgical imaging techniques rely on brightness, which varies depending on how much dye the tumor absorbed and how deep it is in the body—making it hard to distinguish cancer from healthy tissue. Since the glow duration is a stable property of the dye itself, it could help surgeons more reliably spot and remove all cancerous tissue during operations.

Plain English
Researchers studied a type of thyroid tumor called noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) to better understand its diagnosis and treatment. They found that NIFTP rarely led to cancer recurrence after surgery, but the way it was diagnosed often varied, leading to uncertainty in treatment decisions. This highlights the need for clearer guidelines for managing these borderline tumors, which can help doctors take more consistent and effective actions for their patients.

Plain English
Researchers studied a type of thyroid cancer called Hürthle cell carcinoma, which has specific genetic changes that affect energy production in cells. They discovered that these cancer cells are particularly vulnerable to stress from certain harmful molecules due to their genetic makeup. This finding is important because it could lead to new treatments that target this weakness, potentially improving outcomes for patients with this type of cancer.